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Abstract
Microsatellite instability (MSI) testing of colorectal cancers (CRCs) is used to screen
for Lynch syndrome (LS), a hereditary cancer‐predisposition, and can be used to
predict response to immunotherapy. Here, we present a single‐molecule molecular
inversion probe and sequencing‐based MSI assay and demonstrate its clinical validity
according to existing guidelines. We amplified 24 microsatellites in multiplex and
trained a classifier using 98 CRCs, which accommodates marker specific sensitivities
to MSI. Sample classification achieved 100% concordance with the MSI Analysis
System v1.2 (Promega) in three independent cohorts, totaling 220 CRCs. Back-
ward–forward stepwise selection was used to identify a 6‐marker subset of equal
accuracy to the 24‐marker panel. Assessment of assay detection limits showed that
the 24‐marker panel is marginally more robust to sample variables than the 6‐marker
subset, detecting as little as 3% high levels of MSI DNA in sample mixtures, and
requiring a minimum of 10 template molecules to be sequenced per marker for >95%
accuracy. BRAF c.1799 mutation analysis was also included to streamline LS testing,
with all c.1799T>A variants being correctly identified. The assay, therefore, provides
a cheap, robust, automatable, and scalable MSI test with internal quality controls,
suitable for clinical cancer diagnostics.
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1 | INTRODUCTION
Increased microsatellite instability (MSI) is a hallmark of mismatch
repair (MMR) deficiency, which affects approximately one in six
colorectal cancers (CRCs; Boland et al., 1998). Lynch syndrome (LS) is
an inherited predisposition to cancer caused by germline pathogenic
variants affecting one allele of an MMR gene and accounts for
approximately one in five MMR deficient CRCs (Hampel et al., 2008).
MMR deficiency is also associated with tumor response to immune
checkpoint blockade therapy, irrespective of tissue of origin (Le et al.,
2017). Therefore, the assessment of MSI, or MMR, status can inform
patient management and is recommended in all CRCs by national and
international guidelines to screen for LS (Balmana, Balaguer,
Cervantes, & Arnold, 2013; Newland et al., 2017; Stoffel et al.,
2015). Once identified, patients with LS benefit from surveillance
colonoscopy, prophylactic surgery, and chemoprevention (Burn et al.,
2011; Vasen et al., 2013).
MMR status of tumors is commonly assessed by immunohis-
tochemistry (IHC) of MMR proteins, or polymerase chain reaction
(PCR) fragment length analysis (FLA) of microsatellites to detect
increased MSI. MMR deficiency is inferred from the absence of at
least one MMR protein, or high levels of MSI (MSI‐H). MSI‐H is
defined by mutation of ≥30–40% of microsatellites analyzed
(Boland et al., 1998). These methods are highly sensitive and
specific, with reported sensitivities and specificities of 93% and
95% for IHC of all four MMR proteins (Shia, 2008), and 97% and
100% for FLA of mononucleotide repeats (MNRs; Bacher et al.,
2004). IHC and FLA also perform well with respect to other
demands of diagnostic tests. FLA is considered highly reproduci-
ble, with 98% concordance of results observed between indepen-
dent laboratories (Zhang, 2008), although IHC shows some
heterogeneity due to discordant interpretation of variable stain-
ing, and use of different antibodies (Shia, 2008). FLA has been
shown to be reliable when sample tumor cell content is ≥10%
(Berg et al., 2000), and IHC can detect focal MMR deficiency
(Chapusot et al., 2002). Both are also considered to be relatively
cheap and cost‐effective for LS screening (Snowsill et al., 2014).
However, the uptake of MMR deficiency testing has been poor;
only 28% of 152,993 CRC cases were analyzed during 2010–2012
in the USA (Shaikh, Handorf, Meyer, Hall, & Esnaola, 2018), with a
similar proportion being analyzed in the UK This is despite
guidelines recommending testing and estimates that only 1.2% of
LS gene carriers were known to clinical services in the US in 2011
(Hampel & de la Chapelle, 2011). We estimate that only 5% of
carriers are currently known in the UK.
Automated sequence analysis is better suited to high‐throughput
diagnostics than FLA, or IHC, leading to the development of next‐
generation sequencing (NGS)‐based MSI assays that analyze micro-
satellites captured by gene panel sequencing. These determine the
mutation status of each microsatellite from the frequency of length
variants detected, and then use the proportion of microsatellites that
are mutated to classify a sample. Several such classifiers have
reported sensitivities and specificities >95% (Kautto et al., 2016; Zhu
et al., 2018), and have identified samples misclassified by conven-
tional MMR deficiency tests, highlighting that there is no gold
standard reference method (Hause, Pritchard, Shendure, & Salipante,
2016). Gene panel sequencing also allows additional clinically
actionable markers to be simultaneously assessed. For example,
separate testing for the BRAF c.1799T>A variant (p.V600E), following
FLA or IHC, is recommended to increase the specificity of LS
screening (Newland et al., 2017), but both MSI and BRAF can be
analyzed by a single tumor sequencing assay (Hampel et al., 2018).
However, the high cost of gene panel sequencing (Marino et al.,
2018) may be a barrier to its widespread deployment for MSI testing,
or for the detection of LS by MMR gene sequencing. Targeted NGS‐
based MSI assays that use multiplex amplification of specific panels
of microsatellites have been developed that, similar to gene panel‐
based methods, classify samples by the proportion of microsatellites
that are mutated (Gan et al., 2015; Hempelmann et al., 2018;
Hempelmann, Scroggins, Pritchard, & Salipante, 2015; Waalkes et al.,
2018). However, even when using the same method, different marker
proportions can be used as a classification threshold with different
marker sets (Hempelmann et al., 2015; Hempelmann et al., 2018;
Kautto et al., 2016; Waalkes et al., 2018; Zhu et al., 2018), and
thresholds can be uncertain when relatively few microsatellites (<20)
are analyzed (Hempelmann et al., 2015).
We have previously used amplicon sequencing of short (7–12
base pairs [bp]), monomorphic MNRs to classify the MSI status of
CRCs, without needing matched normal tissue (Redford et al.,
2018). Short MNRs were selected as longer (>15 bp) microsatellites
are associated with increased PCR and sequencing error (Fazekas,
Steeves, & Newmaster, 2010), and it has been reported that
9–15 bp microsatellites give the greatest differences in mutation
frequencies between MSI‐H and microsatellite stable (MSS) samples
using NGS (Maruvka et al., 2017). Our method for MSI detection
accounts for the individual sensitivity and specificity of each
marker, and achieved >97% accuracy in 209 CRCs with only 17
markers, using FLA as the reference method (Redford et al., 2018).
However, the protocol required singleplex PCR amplification,
followed by the second round of PCR to prepare the amplicons
for sequencing. Here, we modify this method to develop an MSI
assay suitable for clinical cancer diagnostics. We use single‐
molecule molecular inversion probes (smMIPs; Hiatt, Pritchard,
Salipante, O’Roak, & Shendure, 2013) to amplify in multiplex and
sequence 24 short MNRs, and show that the assay achieves 100%
accuracy with as few as six markers. We also include BRAF c.1799
sequencing for streamlined LS screening (Newland et al., 2017). To
establish the assay is suitable for clinical practice, we follow joint
guidelines from the Association for Molecular Pathology and the
College of American Pathologists (Jennings et al., 2017). This
includes validation of diagnostic accuracy using independent sample
cohorts, assessment of reproducibility and detection limits, the
definition of quality control criteria, and deployment in an
independent diagnostic laboratory.
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2 | MATERIALS AND METHODS
Unless stated otherwise, the manufacturer’s protocols were followed
for each kit or reagent.
2.1 | Patient samples
Nineteen and 73 CRC DNAs were provided by the Department
of Molecular Pathology, University of Edinburgh, UK, and the
Oncogenetics and Hereditary Cancer Group, Complejo Hospitalario
de Navarra, Spain, respectively. These 92 samples were residual
stocks from Redford et al. (2018). An additional 128 CRC DNAs or
CRC formalin‐fixed paraffin‐embedded (FFPE) tissue samples were
provided by the Northern Genetics Service, Newcastle Hospitals
NHS Foundation Trust, UK. Nineteen DNAs extracted from
peripheral blood leukocytes (PBLs), from patients consenting to
sample‐use in assay development, were gifted by K. Wimmer
(Medical University of Innsbruck, Austria) and used as MSS controls.
All CRC samples (Table S1) were independently tested for MMR
deficiency by the contributing laboratory using the MSI Analysis
System v1.2 (Promega); samples with one mutant marker (MSI low)
were considered equivalent to MSS samples (Halford et al., 2002).
Forty‐six of the MSI‐H samples were independently tested for BRAF
c.1799T>A by high‐resolution melt (HRM) curve analysis (Nikiforov
et al., 2009) on a LightCycler 480 (Roche), as part of the LS screening
pipeline at the Northern Genetics Service.
All samples were anonymized by the contributing laboratory, and
analyzed following approval by the NHS Health Research Authority
Research Ethics Committee (13/LO/1514).
2.2 | Cell lines and culture
H9 embryonic stem cell line (WiCell, agreement number 06‐W097)
DNA was a gift from L. Lako (Newcastle University, UK), and used
as an MSS control. HCT116 (CCL‐247; ATCC) and K562 (CCL‐243;
ATCC) cells were gifted by J. Irving (Newcastle University, UK).
HCT116 and K562 cells were grown in the Roswell Park Memorial
Institute growth medium containing 2 mM L‐glutamine (Gibco),
10% fetal bovine serum (Gibco), 60 µg/ml penicillin, and 100 µg/ml
streptomycin (Gibco) at 37°C and 5% CO2. HCT116 cells were
passaged or harvested at 80–90% confluence by decanting expired
growth medium, washing in 5 ml phosphate‐buffered saline
(Gibco), and detaching the cells using 0.05% trypsin–ethylenedia-
minetetraacetic acid (Gibco). K562 cells were passaged or
harvested at a density of 1 × 106cells/ml. DNA extracted from
HCT116 CRC cell line (MLH1 deficient) was used as an MSI‐H
control. DNA extracted from K562 chronic myeloid leukemia cell
line was used as an MSS control.
2.3 | Sample mixtures and dilutions
Mixtures of MSI‐H and MSS samples were created using HCT116 and
PBL DNAs (Table 1). Nine samples, comprising three fresh tissues
(HCT116, H9, and K562 cell lines), and six FFPE tissues (three MSI‐H
CRCs: N021, N068, and N073; and three MSS CRCs: N033, N036,
and N056), were twofold serially diluted in 10mM Tris‐HCl pH 8.5.
2.4 | DNA extraction and quantification
DNA was extracted from FFPE CRC tissue using the GeneRead DNA
FFPE Kit (Qiagen). DNA was extracted from cell lines using the
Wizard Genomic DNA Purification Kit (Promega). DNAs were
quantified using QuBit 2.0 Fluorometer (Invitrogen) and QuBit
dsDNA BR/HS Kits (Invitrogen).
2.5 | Markers and smMIP design
The marker panel includes 24 MNRs, previously published by Redford
et al. (2018), for MSI classification, as well as BRAF c.1799 to screen
for sporadic MSI‐H CRCs (Newland et al., 2017). MIPgen (Boyle,
O’Roak, Martin, Kumar, & Shendure, 2014) was used to generate
smMIP sequences for each marker. MIPgen parameters were: Tag size
6, 0, minimum capture size 120, and maximum capture size 150.
smMIP designs were selected by the following criteria: No common
single nucleotide polymorphisms (SNPs) in the smMIP extension or
ligation arms, a logistic score >0.8, and successful amplification of loci.
Marker loci and smMIP sequences are detailed in Table S2.
2.6 | Oligonucleotide synthesis
smMIPs and primers for amplification and sequencing (Table S3),
were synthesized by and purchased from Metabion.
TABLE 1 Generation of sample mixtures with varying MSI‐H content
MSI‐H cell line DNA content (%) Mixture of DNAs (25 ng/µl)
50.00 10 µl of HCT116 DNA + 10 µl of PBL DNA
25.00 10 µl of 50.00% mixture + 10 µl of PBL DNA
12.50 10 µl of 25.00% mixture + 10 µl of PBL DNA
6.25 10 µl of 12.50% mixture + 10 µl of PBL DNA
3.13 10 µl of 6.25% mixture + 10 µl of PBL DNA
1.56 10 µl of 3.13% mixture + 10 µl of PBL DNA
0.78 10 µl of 1.56% mixture + 10 µl of PBL DNA
Abbreviations: MSI, microsatellite instability; MSI‐H, high levels of MSI; PBL, peripheral blood leukocyte.
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2.7 | smMIP phosphorylation and pooling
smMIPs were individually phosphorylated using 10 U of T4 Poly-
nucleotide Kinase (NEB), 1X T4 DNA Ligase buffer (NEB), and 1 μM
of unphosphorylated smMIP in a 100 µl reaction volume, and
incubated at 37°C for 45min, followed by 80°C for 20min.
Phosphorylated smMIPs were pooled, with specified volumes for
each smMIP to equalize the number of reads from each marker locus,
and diluted using Tris‐EDTA buffer (Sigma) to an average concentra-
tion of 0.1 nM (Table S4).
2.8 | smMIP amplification
smMIP‐multiplexed amplification was based on Hiatt et al. (2013)
using a SensoQuest thermocycler (SensoQuest GmbH), with minor
modifications to the protocol. Herculase II Polymerase (Agilent) was
used during extension and amplification steps for increased fidelity of
microsatellite replication (Fazekas et al., 2010). For amplification, the
thermocycler program used 98°C for 2 min, 30 cycles of 98°C for
15 s, 60°C for 30 s and 72°C for 30 s, followed by 72°C for 2min.
Hundred nanograms of sample DNA was used as a template unless
stated otherwise: The input quantity of CRC sample DNA varied
depending on quantity available (Table S1). smMIP reaction products
(240–270 bp) were analyzed using 3% agarose gel electrophoresis at
80mV for 60min, or a QIAxcel (Qiagen).
2.9 | Library preparation and sequencing
smMIP amplicons were purified using Agencourt AMPure XP Beads
(Beckman Coulter), diluted to 4 nM in 10mM Tris pH 8.5, and pooled
in equal volumes. Libraries were sequenced on a MiSeq (Illumina)
using the Generate FASTQ workflow, paired‐end sequencing, and
custom sequencing primers (Hiatt et al., 2013); sequencing run
statistics are presented in Table S5. FASTQ files are available from
the EMBL‐EBI European Nucleotide Archive, accession number
PRJEB28394.
2.10 | Sequence analysis and MSI classification
Sequence analysis and MSI classification were carried out as
described in by Redford et al. (2018). In brief, sequencing reads
were aligned to the hg19 reference genome using the command
BWA MEM (BWA v0.6.2; Li & Durbin, 2010). smMIP‐based
sequencing assesses the regions of interest in both orientations,
and only base calls supported by both reads of a pair were processed
further. The MSI classifier uses both the frequency and allelic bias of
deletions in the microsatellite markers to type each sample. The
deletion frequency was defined as the proportion of reads that have
a microsatellite length less than the reference length. For samples
heterozygous at the neighboring SNP, the allelic bias of deletions,
that is, whether deletions are preferentially observed in reads
carrying one of the SNP alleles, can be assessed using the Fisher’s
Exact test p value. For each marker, deletion frequency and allelic
bias were dichotomised into two binary traits; deletion frequency is
assessed by whether it is above or below the 95th percentile of the
training MSS samples, and allelic bias is assessed by whether the p
value is above or below .05. A training cohort of samples was used to
estimate the probabilities of observing the different traits for each
marker in MSI‐H and MSS tumors. The (posterior) probability that a
new sample is MSI‐H versus MSS can then be estimated from its
microsatellite deletion frequencies, and the allelic bias of deletions,
using a naïve Bayes approach. A prior probability of .85 that a sample
is MSS was used. The assay score represents the decadic logarithm of
the odds a sample is MSI‐H versus MSS. Scores >0 classify a sample
as MSI‐H, and scores <0 classify a sample as MSS.
2.11 | Statistics and graphics
Analyses were performed in R v3.3.1, and graphs generated with R
package ggplot2. Scripts are available on request.
3 | RESULTS
3.1 | MSI classification is accurate and
reproducible
smMIPs were designed for the 17 short MNR markers previously
described in the singleplex assay of Redford et al. (2018). Two
markers had to be excluded from the panel due to poor amplification
by the smMIP protocol. To supplement this reduced panel, smMIPs
were successfully designed for an additional nine markers taken from
the extended set of Redford et al. (2018), giving a total of 24 short
MNR markers (data not shown). Having defined the marker panel, a
training cohort of 51 MSI‐H and 47 MSS CRCs was used to estimate
classifier parameters. Reclassification of the training samples using
these parameters achieved 100% sensitivity (95% confidence
intervals [CIs]: 93.0–100.0%) and 100% specificity (95% CIs:
92.5–100.0%; Figure 1a). Data filtering using smMIP molecular
barcodes to reduce sequencing error (Hiatt et al., 2013) did not
improve sample separation by the classifier (Supporting Information
S1), and therefore was not employed for MSI classification. The 15
markers remaining from the 17‐marker panel of Redford et al. (2018)
also achieved 100% sensitivity and specificity (data not shown),
indicating redundancy in the marker panel. Backward–forward
stepwise selection was used to define a subset of six short MNRs
(Table S2) with accuracy equal to the 24 marker panel (Figure 1A).
An independent validation cohort of 50 MSI‐H and 49 MSS was
sequenced and analyzed, and 100% sensitivity (95% CIs:
92.9–100.0%) and 100% specificity (95% CIs: 92.8–100.0%) was
again achieved using all 24 markers, and the 6‐marker subset (Figure
1b). To assess assay reproducibility, 16 MSI‐H and 16 MSS CRCs
from the validation cohort were amplified, sequenced, and classified
a second time. The classification was 100% concordant, and scores
were strongly correlated between sample repeats, using both
24 markers (β = .97, R2 = .97), and the 6‐marker subset (β = 1.01,
R2 = .97).
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3.2 | BRAF c.1799T>A variants are accurately
detected
Independent testing of 46 MSI‐H CRCs for BRAF mutation by HRM
had previously identified 14 samples positive for the c.1799T>A
variant. By inclusion of a smMIP targeting BRAF in the assay, these 14
samples were found to have c.1799T>A variant allele frequencies
(VAFs) >5%, a threshold generally considered to be clinically relevant
in cancer diagnostics (Jennings et al., 2017). Of the 32 CRCs that
tested negative, 30 had VAFs ≤0.60%, in line with observed MiSeq
base‐calling error rates of 0.62% (May et al., 2015). The remaining two
samples had VAFs of 1.67% and 1.72%, suggesting they may contain
low‐frequency variants below the detection limit of HRM (Nikiforov
et al., 2009). Consistent with this, when molecular barcodes were used
to reduce sequencing error (Hiatt et al., 2013), these variants were
found at frequencies of 1.82% and 0.46%, respectively (Table S6). This
analysis identified an additional negative sample with a BRAF
c.1799T>A VAF of 0.15%. Concordance (100%) was also observed
for BRAF mutation calling in repeat testing of the 16 MSI‐H and 16
MSS CRCs, with a strong correlation of VAFs (β = .93, R2 = 1.00).
3.3 | MSI classification detects 3% MSI‐H cell line
DNA in sample mixtures
To estimate the minimumMMR deficient tumor cell content required for
a CRC to be classified as MSI‐H, we mixed DNA from HCT116 (a clonal,
MMR deficient CRC cell line) with DNA from nonneoplastic PBLs to
create, in triplicate, sample mixtures containing 0.78–100% DNA from
MSI‐H cells. Across the mixtures, the observed and the theoretically
expected proportion of reads containing insertion–deletion mutations in
each microsatellite were strongly correlated (β=1.03, R2 = .99; Support-
ing Information S2), giving confidence in mixing accuracy. Mixtures
containing ≥3.13% and ≥6.25% DNA from MSI‐H cells were classified as
MSI‐H using the 24‐ and 6‐marker sets, respectively (Figure 2a), results
which are better than or equivalent to FLA (Table S7).
We further investigated the impact of sample heterogeneity on
classification in silico by randomly selecting sequencing reads from
MSI‐H and MSS samples and mixing them in predetermined propor-
tions to create simulated samples (Supporting Information S2). Scores
from simulated samples were strongly correlated with scores from the
mixing of DNAs (β = .97, R2 = .98). Mixing reads from all pairwise
combinations of MSI‐H and MSS samples from the validation cohort
revealed that >95% of mixtures containing ≥25.0% reads from an MSI‐
H CRC were classified as MSI‐H using the 24 marker panels, while
≥27.5% of MSI‐H CRC reads were needed to achieve the same level of
classification accuracy using the 6‐marker panel (Figure 2b). As reads
from MSI‐H CRCs are derived from heterogeneous mixtures of the
tumor and normal tissue, this supports the conclusion that the MSI
classifier is robust to low MMR deficient tumor cell content.
3.4 | MSI classification is accurate when 10 or
more molecules are sequenced per marker
Whilst we found no improvement to classifier performance using
molecular barcodes to correct sequencing error (Supporting
F IGURE 1 MSI classification of CRCs. MSI classifier scores versus diagnosis by the MSI Analysis System v1.2 (Promega) for CRCs analyzed in
(a) the training cohort, and (b) the validation cohort. CRC, colorectal cancer; MNR, mononucleotide repeat; MSI, microsatellite instability; MSI‐
H, high levels of MSI
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Information S1), molecular barcodes can be used to estimate the
number of template molecules sequenced to provide a quality control
metric (Jennings et al., 2017). To establish this, and investigate the
relationship between the number of template molecules sequenced
and the accuracy of classification, we created twofold dilution series
of nine samples, with template quantities ranging from 3.13 to 100 ng
of DNA per reaction. A strong correlation between the input quantity
of template DNA and the number of molecular barcodes detected
across the nine samples (R2 = .99–1.00; Supporting Information S3)
confirmed the accuracy of dilution. Using the 24‐marker panel, all
samples with a mean molecular barcodes per marker ≥75 were
correctly classified, and among these there was no correlation
between the number of molecular barcodes detected and any change
in classifier score, relative to the baseline score from 100 ng of
template DNA (R2 = .10, p = .09; Figure 3a). However, below 75
molecular barcodes per marker, there was marked variability in the
score for three samples (Figure 3a). Results were similar using the 6‐
marker subset, except that one MSS sample with a mean molecular
barcode detected per marker ≥75 was misclassified (Figure 3a). In
agreement with these estimates, only one sample from the training
F IGURE 2 Assay robustness to sample heterogeneity. A, Classifier scores from mixtures of MSI‐H cell line and MSS PBL DNA samples. B,
The proportion of correctly classified samples from 2400 simulated mixture series from the validation cohort reads (dotted line = 0.95). CRC,
colorectal cancer; MNR, mononucleotide repeat; MSS, microsatellite stable; MSI‐H, high levels of MSI; PBL, peripheral blood leukocyte
F IGURE 3 Assay robustness to variation in the quantity of sample DNA. A, Classifier scores from a serial dilution of nine samples, using
3.13–100 ng of template DNA (dotted line = 75 molecular barcodes per marker). B, The proportion of correctly classified samples from 60
simulated dilution series per sample in the validation cohort (dotted line = 0.95). MSS, microsatellite stable; MSI‐H, high levels of MSI; MNR,
mononucleotide repeat
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and validation cohorts had a mean molecular barcode detected per
marker <75 (Table S1), and all were correctly classified with either
the 24‐ or 6‐marker panels.
To explore the minimum number of template molecules that need
to be sequenced for accurate classification, we also performed an in
silico resampling of sequencing data. Analysis of the nine‐sample
dilution series gave a strong correlation between classifier scores
from empirical observations and from resampling (β = .92, R2 = .96;
Supporting Information S3). Resampling of the CRCs included in the
validation cohort was used to increase the number of observations,
and it was found that using the 24‐ and 6‐marker panels, sequencing
of ≥10 and ≥15 molecular barcodes per marker, respectively, gave a
correct classification of >95% of samples (Figure 3b). It should be
noted that these estimates were obtained from resampling high‐
quality sequencing data. Therefore, the mean of 75 molecular
barcodes per marker obtained empirically provides a more con-
servative threshold for diagnostic use.
3.5 | Validation in an independent clinical
laboratory
Assessment of an assay’s performance in an independent clinical
laboratory supports that it is a reproducible method, suitable for
wider adoption (Jennings et al., 2017). To test this, our smMIP‐
based MSI assay was set up by the Northern Genetics Service
(Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne,
UK) using our protocols, and our smMIP and primer oligonucleo-
tides. All other reagents and equipment were distinct from those
used during assay development, and the personnel running the
assay were independent of our research team. Once established, a
further 23 independent CRCs were analyzed using the assay, and it
again achieved 100% sensitivity (95% CIs: 79.4–100.0%) and 100%
specificity (95% CIs: 59.0–100.0%) relative to the MSI Analysis
System v1.2, when classifying samples with both the 24‐ and
6‐marker panels (Figure 4). Although four samples had <75
molecular barcodes per marker detected (Table S1), they were
accurately classified in agreement with reading sampling predic-
tions, and so were not resequenced at a higher depth.
4 | DISCUSSION
The MSI assay presented here achieved 100% accuracy of MSI
classification in 220 CRCs, relative to the MSI Analysis System v1.2
(Promega), using only tumor DNA and as few as six microsatellite
markers. We found no improvement to classifier performance using
molecular barcodes for sequencing error correction (Hiatt et al.,
2013; Supporting Information S1). This is likely due to our use of
short MNRs with flanking SNPs, selected from genome‐wide data,
and classification method. Shorter microsatellites have lower PCR
and sequencing error rates compared with longer microsatellites
(Fazekas et al., 2010), while the SNPs flanking the microsatellites
provide additional discrimination between error and true
microsatellite mutations. Classification by a naïve Bayesian approach
accounts for individual marker sensitivity, specificity, and sequencing
error rate (Redford et al., 2018). However, molecular barcodes are
used in our assay to provide a quality control metric by estimating
the number of independent molecules sequenced (Jennings et al.,
2017). We have also shown, previously, that molecular barcodes are
useful for the detection of much lower frequency microsatellite
variants, found in the PBLs of patients with constitutional mismatch
repair deficiency (CMMRD; Gallon et al., 2019).
To show that the assay is suitable for clinical practice, we tested
its clinical validity according to published guidelines (Jennings et al.,
2017). We validated its accuracy (100%) across three cohorts of
clinical samples, which included poor‐quality DNA samples from
FFPE tissue, and 23 CRCs analyzed by an independent diagnostic
laboratory. We also observed 100% classification concordance in
repeat testing and assessed robustness to sample heterogeneity
using sample mixing, detecting 3% and 6% MSI‐H cell line DNA with
the 24‐ and 6‐marker panels, respectively. Depending on the marker
panel used, we estimate that 10 or 15 molecular barcodes per marker
are required for correct classification of >95% of samples. We have,
therefore, shown that it is possible to accurately determine MSI
status using only six markers, a fraction of the number required by
other NGS‐based MSI assays (Kautto et al., 2016; Waalkes et al.,
2018; Zhu et al., 2018), and observed only a small reduction in assay
F IGURE 4 Assay validation in an independent laboratory. MSI
classifier scores versus diagnosis by the MSI Analysis System v1.2
(Promega) for 23 CRCs tested by the Northern Genetics Service
(Newcastle Hospitals NHS Foundation Trust, Newcastle, UK).
CRC, colorectal cancer; MSI, microsatellite instability; MSI‐H, high
levels of MSI
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robustness using this subset rather than the 24‐marker panel. The
requirement of other NGS‐based MSI classifiers for larger marker
panels may be explained by the classification method, as assessing
the proportion of mutated microsatellites gives equal diagnostic
weight to each marker and does not account for the variable
influence of MMR deficiency on the mutation of individual micro-
satellites (Dietmaier et al., 1997).
Marker number has a significant impact on cost, and with only six
markers, plus BRAF c.1799, our reagent cost estimates range from
£5.55–6.81 per sample, depending on the capacity of the MiSeq kit
used (Supporting Information S4). The 24 marker set may, however,
be preferred for a variety of reasons: It could provide protection
against allele or marker drop out due to technical variation, somatic
events within tumors, or population‐specific sequence variants. It
may also enhance the clinical utility of the assay, as it increases the
power of the internal sample traceability provided by the SNPs linked
to each marker. For instance, using the allele frequencies observed in
the training cohort, the probability of any two individuals sharing the
same genotype is 3.8 × 10−3 from the 6‐marker subset, but
3.6 × 10−10 when 24 markers are used (Table S2).
The clinical demand for MSI analysis may increase, driven by the
need to predict patient response to immune checkpoint blockade
therapy across multiple cancer types (Le et al., 2017). The frequency
of mutations in noncoding microsatellites has been shown to be
equivalent between different cancer types (Cortes‐Ciriano, Lee, Park,
Kim, & Park, 2017), and we have previously shown that the 24
markers analyzed here can detect CMMRD from PBL DNA (Gallon
et al., 2019), making it likely that our assay will be suitable for MSI
detection in extra‐colonic tissues. For the identification of LS through
screening all CRCs for MMR deficiency, the inclusion of BRAF c.1799
avoids expenditure on additional tests as a single tumor assay is
required before germline testing. It also demonstrates the modularity
of the assay, which can be expanded to cover additional clinically
relevant markers, or adapted to different tumor types, with ease
since thousands of smMIPs can be multiplexed (Hiatt et al., 2013;
Oud et al., 2017). MLH1 promoter methylation is an alternative
marker to the BRAF c.1799T>A variant to exclude sporadic MMR
deficient patients with CRC from germline testing and has superior
specificity for LS detection (Pérez‐Carbonell et al., 2010). However,
this also excludes MLH1 mutation carriers who have methylation as
the second hit in their tumor (Moreira et al., 2015), or have germline
epimutations (Suter, Martin, & Ward, 2004).
In summary, the MSI assay outlined here is accurate, reprodu-
cible, robust to sample heterogeneity, and includes both internal
quality controls and sample identification. The automatable labora-
tory workflow and analysis, and the need for as few as six
microsatellite markers at moderate read depths provide a cheap
and scalable option for high‐throughput MMR deficiency testing.
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